AngioSoma Financials
| GSTC Stock | USD 0.0009 0.0001 12.50% |
AngioSoma |
Understanding current and past AngioSoma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of AngioSoma's financial statements are interrelated, with each one affecting the others. For example, an increase in AngioSoma's assets may result in an increase in income on the income statement.
The data published in AngioSoma's official financial statements usually reflect AngioSoma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of AngioSoma. For example, before you start analyzing numbers published by AngioSoma accountants, it's critical to develop an understanding of what AngioSoma's liquidity, profitability, and earnings quality are in the context of the AngioSoma space in which it operates.
Please note, the presentation of AngioSoma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AngioSoma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in AngioSoma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AngioSoma. Please utilize our Beneish M Score to check the likelihood of AngioSoma's management manipulating its earnings.
AngioSoma Stock Summary
AngioSoma competes with Microsoft, Apple, NVIDIA, Alphabet, and Amazon. GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. The company was incorporated in 2016 and is based in Richland, Washington. Globestar Therapeutics is traded on OTC Exchange in the United States.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US37960P1049 |
| Business Address | 719 Jadewin Avenue, |
| Benchmark | NYSE Composite |
| Website | www.globestarthera.com |
| Phone | 206 451 1970 |
| Currency | USD - US Dollar |
You should never invest in AngioSoma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of AngioSoma Pink Sheet, because this is throwing your money away. Analyzing the key information contained in AngioSoma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
AngioSoma Key Financial Ratios
Generally speaking, AngioSoma's financial ratios allow both analysts and investors to convert raw data from AngioSoma's financial statements into concise, actionable information that can be used to evaluate the performance of AngioSoma over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that AngioSoma reports annually and quarterly.AngioSoma Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining AngioSoma's current stock value. Our valuation model uses many indicators to compare AngioSoma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AngioSoma competition to find correlations between indicators driving AngioSoma's intrinsic value. More Info.AngioSoma is rated below average in return on asset category among related companies. It is rated below average in current valuation category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value AngioSoma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for AngioSoma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AngioSoma's earnings, one of the primary drivers of an investment's value.AngioSoma Systematic Risk
AngioSoma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. AngioSoma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on AngioSoma correlated with the market. If Beta is less than 0 AngioSoma generally moves in the opposite direction as compared to the market. If AngioSoma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one AngioSoma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of AngioSoma is generally in the same direction as the market. If Beta > 1 AngioSoma moves generally in the same direction as, but more than the movement of the benchmark.
About AngioSoma Financials
What exactly are AngioSoma Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include AngioSoma's income statement, its balance sheet, and the statement of cash flows. Potential AngioSoma investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although AngioSoma investors may use each financial statement separately, they are all related. The changes in AngioSoma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on AngioSoma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze AngioSoma Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as AngioSoma is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of AngioSoma has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if AngioSoma's financials are consistent with your investment objective using the following steps:- Review AngioSoma's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand AngioSoma's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare AngioSoma's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if AngioSoma's stock is overvalued or undervalued.
AngioSoma May 5, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of AngioSoma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of AngioSoma. We use our internally-developed statistical techniques to arrive at the intrinsic value of AngioSoma based on widely used predictive technical indicators. In general, we focus on analyzing AngioSoma Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build AngioSoma's daily price indicators and compare them against related drivers.
| Downside Deviation | 18.47 | |||
| Information Ratio | 0.0308 | |||
| Maximum Drawdown | 106.25 | |||
| Value At Risk | (23.08) | |||
| Potential Upside | 16.67 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in AngioSoma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for AngioSoma Pink Sheet analysis
When running AngioSoma's price analysis, check to measure AngioSoma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AngioSoma is operating at the current time. Most of AngioSoma's value examination focuses on studying past and present price action to predict the probability of AngioSoma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AngioSoma's price. Additionally, you may evaluate how the addition of AngioSoma to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |